Regular Research ArticlesEffects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease
Section snippets
Participant Screening
The DPS enrolls participants with incident dementia screened from the population of Cache County, Utah via procedures of the Cache County Study on Memory, Health, and Aging (CCSMHA). The protocols have been reported in detail elsewhere.21 Briefly, of the 5677 permanent residents of Cache County Utah aged 65 or older on January 1, 1995, 5092 (90%) enrolled in the study and underwent a multistage screening and assessment. Individuals with prevalent dementia were identified at the initial study
RESULTS
Of the 216 participants with incident AD and who had baseline CDR and MMSE scores, 135 (62.5%) had at least 1 additional follow-up. The flow chart for recruitment and attrition have been previously published.31 The attrition between baseline and follow-up was attributable to death in 59 participants, refusal in 11 participants, and not yet reached time for follow-up in 11 participants. The mean duration from baseline to follow-up visit was 1.6 years (SD 6.5), and subsequent visits were biennial
CONCLUSION
In a population-based sample of 216 participants with incident AD followed in a prospective longitudinal manner for a mean of 3.14 years, the use of statins and beta-blockers at baseline was associated with a slower rate of functional decline as measured by the CDR-Sum. CDR-Sum increased 1.69 points annually overall indicating that the typical course of AD in this cohort was progressive functional decline. This rate of decline was slower than the 2.9 point annual decline reported by Bhargava et
References (43)
- et al.
15-year longitudinal study of blood pressure and dementia
Lancet
(1996) - et al.
Statins and the risk of dementia
Lancet
(2000) - et al.
Statin use and the risk of Alzheimer's disease: the MIRAGE study
Alzheimer's Dementia
(2006) - et al.
PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
Lancet
(2002) - et al.
Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: study on Cognition and prognosis in the elderly (SCOPE)
Am J Hypertens
(2005) - et al.
The age-dependent relation of blood pressure to cognitive function and dementia
Lancet Neurol
(2005) - et al.
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Cholesterol and Alzheimer's disease–is there a relation?
Mech Ageing Dev
(2006) - et al.
Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
Neurobiol Dis
(2000) - et al.
Alzheimer disease in the US population: prevalence estimates using the 2000 census
Arch Neurol
(2003)
Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study
BMJ
Diabetes mellitus and the risk of dementia: the rotterdam study
Neurology
Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment
Neurol Res
Plasma total cholesterol level as a risk factor for Alzheimer disease: the framingham study
Arch Intern Med
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
Arch Neurol
Statin use and the risk of incident dementia: the cardiovascular health study
Arch Neurol
Do statins reduce risk of incident dementia and Alzheimer disease? the cache county study
Arch Gen Psychiatry
Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study
Neurology
Antihypertensive medication use and incident Alzheimer disease: the cache county study
Arch Neurol
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial
Ann Neurol
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results
Arch Neurol
Cited by (110)
Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles
2024, Biomedicine and PharmacotherapyLean-to-fat tissue ratio as a risk factor for cognitive impairment in patients undergoing maintenance hemodialysis
2023, Journal of Psychosomatic ResearchModulation of L-type calcium channels in Alzheimer's disease: A potential therapeutic target
2023, Computational and Structural Biotechnology JournalGenetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD study
2022, Genes and DiseasesThe Locus Coeruleus – Noradrenaline system: Looking into Alzheimer's therapeutics with rose coloured glasses
2022, Biomedicine and Pharmacotherapy
Statistical analyses performed by PBR and MMM.
These results have been presented previously in part at the American College of Neuropsychopharmacology 45th Annual Meeting, Hollywood, Florida, December 3–7, 2006.